Literature DB >> 33388322

HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019.

Laia Bruni1, Anna Saura-Lázaro2, Alexandra Montoliu3, Maria Brotons4, Laia Alemany5, Mamadou Saliou Diallo6, Oya Zeren Afsar7, D Scott LaMontagne8, Liudmila Mosina9, Marcela Contreras10, Martha Velandia-González11, Roberta Pastore12, Marta Gacic-Dobo13, Paul Bloem14.   

Abstract

WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently approved global strategy for cervical cancer elimination as a public health problem. As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 (6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated at 15%. There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, specially ensuring the most populous countries introduce, and further improving program performance globally.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33388322     DOI: 10.1016/j.ypmed.2020.106399

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  59 in total

1.  Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.

Authors:  Carolina Porras; Joshua N Sampson; Rolando Herrero; Mitchell H Gail; Bernal Cortés; Allan Hildesheim; Jean Cyr; Byron Romero; John T Schiller; Christian Montero; Ligia A Pinto; John Schussler; Karla Coronado; Mónica S Sierra; Jane J Kim; Catherine M Torres; Loretto Carvajal; Sarah Wagner; Nicole G Campos; Rebecca Ocampo; Troy J Kemp; Michael Zuniga; Douglas R Lowy; Carlos Avila; Stephen Chanock; Ariane Castrillo; Yenory Estrada; Gloriana Barrientos; Cindy Monge; María Y Oconitrillo; Aimée R Kreimer
Journal:  Vaccine       Date:  2021-11-29       Impact factor: 3.641

2.  Bioengineering Approaches to Improve Gynecological Cancer Outcomes.

Authors:  Ali Abbaspour; Andrea L Casillas; Stephanie M McGregor; Pamela K Kreeger
Journal:  Curr Opin Biomed Eng       Date:  2022-03-30

3.  3a edizione Giornate della ricerca scientifica e delle esperienze professionali dei giovani: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) 25-26 marzo 2022.

Authors: 
Journal:  J Prev Med Hyg       Date:  2022-07-06

Review 4.  The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes.

Authors:  Susan Yuill; Louiza S Velentzis; Megan Smith; Sam Egger; C David Wrede; Deborah Bateson; Marc Arbyn; Karen Canfell
Journal:  Hum Vaccin Immunother       Date:  2021-10-03       Impact factor: 4.526

5.  Human papillomavirus vaccination uptake and its associated factors among adolescent school girls in Ambo town, Oromia region, Ethiopia, 2020.

Authors:  Mulugeta W/Mariam Beyen; Gizachew Abdissa Bulto; Eshetu Ejeta Chaka; Bikila Tefera Debelo; Ephrem Yohannes Roga; Negash Wakgari; Kababa Temesgen Danusa; Daniel Belema Fekene
Journal:  PLoS One       Date:  2022-07-13       Impact factor: 3.752

6.  Risk factors and communities disproportionately affected by cervical cancer in the Russian Federation: A national population-based study.

Authors:  Anastasiya Muntyanu; Vladimir Nechaev; Elena Pastukhova; James Logan; Elham Rahme; Elena Netchiporouk; Andrei Zubarev; Ivan V Litvinov
Journal:  Lancet Reg Health Eur       Date:  2022-06-30

Review 7.  False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health.

Authors:  Anna Macios; Andrzej Nowakowski
Journal:  Diagnostics (Basel)       Date:  2022-06-20

Review 8.  Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines.

Authors:  Ryan C V Lintao; Leslie Faye T Cando; Glenmarie Angelica S Perias; Ourlad Alzeus G Tantengco; Ian Kim B Tabios; Clarissa L Velayo; Sheriah Laine M de Paz-Silava
Journal:  Front Med (Lausanne)       Date:  2022-06-20

Review 9.  High-burden Cancers in Middle-income Countries: A Review of Prevention and Early Detection Strategies Targeting At-risk Populations.

Authors:  Anna J Dare; Gregory C Knapp; Anya Romanoff; Olalekan Olasehinde; Olusola C Famurewa; Akinwumi O Komolafe; Samuel Olatoke; Aba Katung; Olusegun I Alatise; T Peter Kingham
Journal:  Cancer Prev Res (Phila)       Date:  2021-09-10

10.  A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer.

Authors:  Nicole G Campos; Maria Demarco; Laia Bruni; Kanan T Desai; Julia C Gage; Sally N Adebamowo; Silvia de Sanjose; Jane J Kim; Mark Schiffman
Journal:  Prev Med       Date:  2021-03-04       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.